Premium
C‐terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease
Author(s) -
De Vos Ann,
Jacobs Dirk,
Struyfs Hanne,
Fransen Erik,
Andersson Kerstin,
Portelius Erik,
Andreasson Ulf,
De Surgeloose Didier,
Hernalsteen Daniëlle,
Sleegers Kristel,
Robberecht Caroline,
Van Broeckhoven Christine,
Zetterberg Henrik,
Blennow Kaj,
Engelborghs Sebastiaan,
Vanmechelen Eugeen
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.05.012
Subject(s) - neurogranin , cerebrospinal fluid , biomarker , medicine , disease , dementia , endocrinology , chemistry , biochemistry , enzyme , protein kinase c
Biomarkers monitoring synaptic degeneration/loss would be valuable for Alzheimer's disease (AD) diagnosis. Postsynaptic protein neurogranin may be a promising cerebrospinal fluid (CSF) biomarker but has not yet been evaluated as a plasma biomarker. Methods Using an in‐house designed prototype enzyme‐linked immunosorbent assay (ELISA) targeting neurogranin C‐terminally, we studied neurogranin in paired CSF/plasma samples of controls (n = 29) versus patients experiencing MCI, or dementia, due to AD (in total n = 59). Results CSF neurogranin was increased in AD and positively correlated with CSF tau, whereas there was a negative relationship between CSF neurogranin (and tau) and CSF Aβ 1–42 /Aβ 1–40 . No differences were detected in plasma neurogranin between controls and AD. Also, there was no correlation between CSF and plasma neurogranin, excluding confounding effects of the latter. Discussion This study strengthens the potential of neurogranin as an AD CSF biomarker, which now needs validation in larger studies. As tools, straightforward immunoassays can be used, as demonstrated by the described ELISA.